Lv3
294 积分 2024-12-13 加入
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
2个月前
已完结
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
2个月前
已完结
Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study
2个月前
已完结
Interstitial lung diseases
3个月前
已完结
TREM2 overexpression rescues cognitive deficits in APP/PS1 transgenic mice by reducing neuroinflammation via the JAK/STAT/SOCS signaling pathway
8个月前
已完结
Targeting the JAK/STAT3/SOCS signaling pathway in Alzheimer's disease
8个月前
已完结
阿尔茨海默病疾病修饰治疗药物临床试验专家共识（2025版）
8个月前
已完结
Cancer of the prostate; general considerations
8个月前
已关闭
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents
8个月前
已完结
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata
8个月前
已完结
皖公网安备34019202002308
